Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Donor leukocyte transfusions for leukemic relapse

F van Rhee1, H J Kolb

  • 1Adult Leukaemia Unit, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK.

Current Opinion in Hematology
|November 1, 1995
PubMed
Summary

Donor lymphocyte infusions can successfully treat recurrent leukemia, especially chronic myelogenous leukemia, after bone marrow transplants. However, complications like graft-versus-host disease and marrow aplasia require careful management.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Conversion of AML-blasts to leukemia-derived dendritic cells (DCleu) in 'DC-culture-media' shifts correlations of released chemokines with antileukemic T-cell reactions.

Immunobiology·2021
Same author

Serum Chemokine-release Profiles in AML-patients Might Contribute to Predict the Clinical Course of the Disease.

Immunological investigations·2019
Same author

Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma.

Leukemia·2018
Same author

Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing.

Nature communications·2017
Same author

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.

Leukemia·2017
Same author

Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker.

Blood cancer journal·2017

Area of Science:

  • Hematology
  • Oncology
  • Immunotherapy

Background:

  • Relapsed leukemia post-bone marrow transplant (BMT) presents significant challenges.
  • Donor lymphocyte infusions (DLIs) are a potential immunotherapy strategy.

Purpose of the Study:

  • To evaluate the efficacy and safety of DLIs for treating recurrent leukemia after BMT.
  • To explore the mechanisms and optimal timing of DLI therapy.

Main Methods:

  • Analysis of patient outcomes receiving DLIs for various leukemia types post-BMT.
  • Observation of complications and response patterns.

Main Results:

  • Successful treatment in most chronic myelogenous leukemia (CML) and some acute myeloid leukemia (AML) / myelodysplastic syndrome (MDS) patients.

Related Experiment Videos

  • Less effective in acute lymphoblastic leukemia (ALL) and advanced CML.
  • Graft-versus-host disease (GVHD) and marrow aplasia were key complications.
  • Hematopoietic recovery possible post-aplasia with donor marrow infusion.
  • Interferon-alpha role requires further study.

    • Conclusions:

    • DLIs show promise for relapsed leukemia post-BMT, particularly CML.
    • GVHD and aplasia are significant risks requiring management strategies.
    • Further research is needed to clarify DLI mechanisms and optimize treatment protocols.